O'NEIL PATRICK R. sold $246K of IONS
O'NEIL PATRICK R. (EVP CLO & General Counsel) sold 3,069 shares of IONIS PHARMACEUTICALS INC (IONS) at $80.00 ($0.25M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s holdings (61,470 shares after sale) but does not introduce new company-specific fundamentals (no guidance, trial, or regulatory updates).
Market read
Traders may note insider selling as a sentiment datapoint, but the planned nature and lack of new fundamentals keep impact limited.
What to watch
The article provides only the sale details; it does not include any concurrent buys, option exercises, or changes in company outlook that would strengthen a directional thesis.
Background
This is an SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals (IONS) by Patrick R. O’Neil, EVP CLO & General Counsel.
Ticker impact
Ionis Pharmaceuticals disclosed an EVP/general counsel open-market sale of 3,069 shares at $80/share under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale.
The filing is a scheduled open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.
Market effects
Minimal read-through for biotech/pharma sector; this is a single-officer transaction without new clinical/regulatory catalysts.
None.
None.
Counterpoint
A 10b5-1 sale can be purely planned liquidity management and may not reflect negative expectations.
Key entities
- issuerIONIS PHARMACEUTICALS INC
Company whose insider transaction was reported on Form 4.
- insiderO'NEIL PATRICK R.
EVP CLO & General Counsel who sold shares under a pre-arranged 10b5-1 plan.
